Ryvu Therapeutics provides an update on the progress of RVU120 Phase I studies in patients with solid tumors and AML/HR-MDS, and presents the updated development plan for RVU120
Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)
Ryvu Therapeutics enters into a PLN 62.3 million financing agreement with the Medical Research Agency to conduct a Phase II clinical trial of RVU120 in combination therapy
Ryvu Therapeutics Announces Entering into Agreement in the Area of Securing Venetoclax Supply Chain for RVU120 Phase II Clinical Trial in Combination Therapy in Hematology
Ryvu Therapeutics enters into two agreements with Clinscience, part of the NEUCA Group, in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology
Ryvu Therapeutics enters into two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials
